Cargando…

Glucagon-like peptide-1 receptor agonists and the risk of cardiovascular events in diabetes patients surviving an acute myocardial infarction

AIMS: Trial evidence indicates that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of cardiovascular (CV) events in patients with diabetes and myocardial infarction (MI). We aimed to expand this observation to routine care settings. METHODS AND RESULTS: Prospective observa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trevisan, Marco, Fu, Edouard L, Szummer, Karolina, Norhammar, Anna, Lundman, Pia, Wanner, Christoph, Sjölander, Arvid, Jernberg, Tomas, Carrero, Juan Jesus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957901/ https://www.ncbi.nlm.nih.gov/pubmed/31999317 http://dx.doi.org/10.1093/ehjcvp/pvaa004

Ejemplares similares

Association Between Mineralocorticoid Receptor Antagonist Use and Outcome in Myocardial Infarction Patients With Heart Failure
por: Löfman, Ida, et al.
Publicado: (2018)

Association of Ischemic and Bleeding Events With Mortality Among Patients in Sweden With Recent Acute Myocardial Infarction Receiving Antithrombotic Therapy
por: Simonsson, Moa, et al.
Publicado: (2022)

Diabetes, metformin and glucose lowering therapies after myocardial infarction: Insights from the SWEDEHEART registry
por: Ritsinger, Viveca, et al.
Publicado: (2020)

Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study
por: Allahyari, Ali, et al.
Publicado: (2020)

hsCRP Level and the Risk of Death or Recurrent Cardiovascular Events in Patients With Myocardial Infarction: a Healthcare‐Based Study
por: Carrero, Juan Jesus, et al.
Publicado: (2019)

Comparison between ticagrelor and clopidogrel in myocardial infarction patients with high bleeding risk
por: Tjerkaski, Jonathan, et al.
Publicado: (2023)

Intensity of and Adherence to Lipid‐Lowering Therapy as Predictors of Major Adverse Cardiovascular Outcomes in Patients With Coronary Heart Disease
por: Mazhar, Faizan, et al.
Publicado: (2022)

Development and Validation of a Novel Risk Score for In‐Hospital Major Bleeding in Acute Myocardial Infarction:—The SWEDEHEART Score
por: Simonsson, Moa, et al.
Publicado: (2019)

Long-term prognosis in patients with acute myocardial infarction and newly detected glucose abnormalities: predictive value of oral glucose tolerance test and HbA1c
por: Karayiannides, Stelios, et al.
Publicado: (2021)

Low-density lipoprotein-cholesterol target attainment according to the 2011 and 2016 ESC/EAS dyslipidaemia guidelines in patients with a recent myocardial infarction: nationwide cohort study, 2013–17
por: Allahyari, Ali, et al.
Publicado: (2020)

Sex Differences in Treatments, Relative Survival, and Excess Mortality Following Acute Myocardial Infarction: National Cohort Study Using the SWEDEHEART Registry
por: Alabas, Oras A, et al.
Publicado: (2017)

Long‐term Cardiovascular Outcomes in Patients With Chronic Kidney Disease Undergoing Coronary Artery Bypass Graft Surgery for Acute Coronary Syndromes
por: Holzmann, Martin, et al.
Publicado: (2014)

Interphysician agreement on subclassification of myocardial infarction
por: Gard, Anton, et al.
Publicado: (2018)

Risk factors for worsening renal function and their association with long-term mortality following transcatheter aortic valve implantation: data from the SWEDEHEART registry
por: Vavilis, Georgios, et al.
Publicado: (2017)

Temporal trends in cardiovascular risk factors, lifestyle and secondary preventive medication for patients with myocardial infarction attending cardiac rehabilitation in Sweden 2006–2019: a registry-based cohort study
por: Leosdottir, Margret, et al.
Publicado: (2023)

Patterns of chronic and transient hyperkalaemia and clinically important outcomes in patients with chronic kidney disease
por: Trevisan, Marco, et al.
Publicado: (2021)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995–2014
por: Szummer, Karolina, et al.
Publicado: (2017)

Validation of risk scores for ischaemic stroke in atrial fibrillation across the spectrum of kidney function
por: de Jong, Ype, et al.
Publicado: (2021)

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
por: Kang, Yu Mi, et al.
Publicado: (2016)

How glucagon-like peptide 1 receptor agonists work
por: Andreasen, Christine Rode, et al.
Publicado: (2021)

Novel glucose-lowering drugs and the risk of acute kidney injury in routine care; the Stockholm CREAtinine Measurements (SCREAM) project
por: Alkas, Jim, et al.
Publicado: (2022)

Prevalence and prognostic impact of kidney disease on heart failure patients
por: Löfman, Ida, et al.
Publicado: (2016)

Synthesis and biological evaluation of glucagon-like peptide-1 receptor agonists
por: Zhang, Yu-Juan, et al.
Publicado: (2013)

Glucagon‐like peptide‐1 receptor agonists and their effects on weight reduction
por: Shin, Shyi‐Jang
Publicado: (2012)

Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
por: Hinnen, Deborah
Publicado: (2017)

The potential of glucagon-like peptide-1 receptor agonists in heart failure
por: Kreiner, Frederik Flindt, et al.
Publicado: (2022)

Glucagon-like peptide-1 receptor agonists in patients treated with antipsychotics
por: Delgado, A., et al.
Publicado: (2021)

Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management
por: Wojtara, Magda, et al.
Publicado: (2023)

Impaired fasting glucose: a risk factor for atrial fibrillation and heart failure
por: Lind, Viktor, et al.
Publicado: (2021)

Factors affecting pre-end-stage kidney disease haemoglobin control and outcomes following dialysis initiation: a nationwide study
por: Xu, Yang, et al.
Publicado: (2021)

Upper and/or lower gastrointestinal adverse events with glucagon‐like peptide‐1 receptor agonists: Incidence and consequences
por: Horowitz, Michael, et al.
Publicado: (2017)

Initiation of sodium polystyrene sulphonate and the risk of gastrointestinal adverse events in advanced chronic kidney disease: a nationwide study
por: Laureati, Paola, et al.
Publicado: (2019)

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
por: Saraiva, Francisco Kerr, et al.
Publicado: (2014)

A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide
por: Gurung, Tara, et al.
Publicado: (2015)

Differential effects of glucagon-like peptide-1 receptor agonists on heart rate
por: Lorenz, Martin, et al.
Publicado: (2017)

Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists
por: Madsbad, Sten
Publicado: (2015)

Patient preferences for glucagon-like peptide 1 receptor–agonist treatment attributes
por: Thieu, Vivian T, et al.
Publicado: (2019)

Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Ameliorates the Development of Periodontitis
por: Sawada, Noritaka, et al.
Publicado: (2020)

Peptidyl and Non-Peptidyl Oral Glucagon-Like Peptide-1 Receptor Agonists
por: Choe, Hun Jee, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3oaph710btfubn5t1j2b1li400